Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Nair, Sajitha ^a,b   Bora Singhal, Namrata ^a   Perumal, Deepak ^a,c   Chellappan, Srikumar ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cell proliferation; ID1; NRSF; Transcriptional repression; ZBP89

Indexed keywords

DNA; INHIBITOR OF DIFFERENTIATION 1; NEURON RESTRICTIVE SILENCER FACTOR; NICOTINE; NICOTINIC RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZINC BINDING PROTEIN; ZINC BINDING PROTEIN 89; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; RE1-SILENCING TRANSCRIPTION FACTOR; REPRESSOR PROTEIN; STATHMIN; STMN3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; ZNF148 PROTEIN, HUMAN; GSPT1 PROTEIN; INHIBITOR OF DNA BINDING DIFFERENTIATION 1; PROTEIN; STATHMIN LIKE 3;

ARTICLE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GSPT1 GENE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; ONCOGENE; PROTEIN DEPLETION; PROTEIN DNA BINDING; REDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATHMIN LIKE3 GENE; CELL MOTION; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION; WOUND HEALING; MICROTUBULE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NICOTINE; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; STATHMIN; TRANSCRIPTION FACTORS; UP-REGULATION; WOUND HEALING;

EID: 84904273422     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-173     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Zaric B, Stojsic V, Tepavac A, Sarcev T, Zarogoulidis P, Darwiche K, Tsakiridis K, Karapantzos I, Kesisis G, Kougioumtzi I, Katsikogiannis N, Machairiotis N, Stylianaki A, Foroulis CN, Zarogoulidis K, Perin B. Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013, 5:S371-S377.
3. Binder D, Hegenbarth K. Emerging options for the management of non-small cell lung cancer. Clin Med Insights Oncol 2013, 7:221-234.
4. Hecht S. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbeck's Arch Surg 2006, 391:603-613.
5. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999, 91:1194-1210.
6. Bunn PA. Worldwide overview of the current status of lung cancer diagnosis and treatment. Arch Pathol Lab Med 2012, 136:1478-1481.
7. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007, 6:746-762.
8. Albuquerque EX, Pereira EFR, Alkondon M, Rogers SW. Mammalian Nicotinic Acetylcholine receptors: from structure to function. Physiol Rev 2009, 89:73-120.
9. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006, 116:2208-2217.
10. Shin VY, Jin HC, Ng EKO, Yu J, Leung WK, Cho CH, Sung JJY. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: involvement of nicotinic acetylcholine receptor (nAChR) and β-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 2008, 233:254-261.
11. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001, 7:833-839.
12. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, Haura E, Chellappan S. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009, 124:36-45.
13. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, Chellappan S. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 2009, 4:e7524.
14. Trevino JG, Pillai S, Kunigal S, Singh S, Fulp WJ, Centeno BA, Chellappan SP. Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Neoplasia 2012, 14:1102-1114.
15. Inoue A, Nukiwa T. Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med 2005, 2:e13.
16. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23:857-865.
17. Van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 2007, 18:99-103.
18. Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to Nicotinic Acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol 2011, 31:3052-3067.
19. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000, 113:3897-3905.
20. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. Cancer Cell 2003, 3:525-530.
21. Bhattacharya R, Kowalski J, Larson AR, Brock M, Alani RM. Id1 promotes tumor cell migration in nonsmall cell lung cancers. J Oncol 2010, 2010:856105.
22. Ling M-T, Wang X, Zhang X, Wong Y-C. The multiple roles of Id-1 in cancer progression. Differentiation 2006, 74:481-487.
23. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990, 61:49-59.
24. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P, Breuhahn K. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 2009, 69:2234-2243.
25. Brito M, Malta-Vacas J, Carmona B, Aires C, Costa P, Martins AP, Ramos S, Conde AR, Monteiro C. Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility. Carcinogenesis 2005, 26:2046-2049.
26. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
27. Drews V, Shi K, Haan G, Meisler M. Identification of evolutionarily conserved, functional noncoding elements in the promoter region of the sodium channel gene SCN8A. Mamm Genome 2007, 18:723-731.
28. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004, 93:242-250.
29. Niethammer P, Bastiaens P, Karsenti E. Stathmin-Tubulin interaction gradients in motile and mitotic cells. Science 2004, 303:1862-1866.
30. Yeap YYC, Ng IHW, Badrian B, Nguyen TV, Yip YY, Dhillon AS, Mutsaers SE, Silke J, Bogoyevitch MA, Ng DCH. c-Jun N-terminal kinase/c-Jun inhibits fibroblast proliferation by negatively regulating the levels of stathmin/oncoprotein 18. Biochem J 2010, 430:345-354.
31. Ng DCH, Lim CP, Lin BH, Zhang T, Cao X. SCG10-like protein (SCLIP) is a STAT3-interacting protein involved in maintaining epithelial morphology in MCF-7 breast cancer cells. Biochem J 2009, 425:95-105.
32. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, Breuhahn K. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007, 46:759-768.
33. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, Canzonieri V, D'Andrea S, Zucchetto A, Friedl P, Colombatti A, Baldassarre G. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 2008, 19:2003-2013.
34. Chen G, Wang H, Gharib TG, Huang C-C, Thomas DG, Shedden KA, Kuick R, Taylor JMG, Kardia SLR, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Overexpression of Oncoprotein 18 correlates with poor differentiation in lung Adenocarcinomas. Mol Cell Proteomics 2003, 2:107-116.
35. Kavallaris M, Ng DCH, Byrne F. Stathmin and Cancer 2012, 259-284. New York,NY: Humana Press, Cytoskeleton and Human Disease.
36. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2006, 94:717-723.
37. Ozawa K, Murakami Y, Eki T, Yokoyama K, Soeda E, Hoshino S-I, Ui M, Hanaoka F. Mapping of the humanGSPT1 gene, a human homolog of the yeastGST1 gene, to chromosomal band 16p13.1. Somat Cell Mol Genet 1992, 18:189-194.
38. Malta-Vacas J, Ferreira P, Monteiro C, Brito M. Differential expression of GSPT1 GGCn alleles in cancer. Cancer Genet Cytogenet 2009, 195:132-142.
39. Volkov K, Osipov K, Valouev I, Inge-Vechtomov S, Mironova L. N-terminal extension of Saccharomyces cerevisiae translation termination factor eRF3 influences the suppression efficiency of sup35 mutations. FEMS Yeast Res 2007, 7:357-365.
40. Kodama H, Ito K, Nakamura Y. The role of N-terminal domain of translational release factor eRF3 for the control of functionality and stability in S. cerevisiae. Genes Cells 2007, 12:639-650.
41. S-i H, Imai M, Mizutani M, Kikuchi Y, Hanaoka F, Ui M, Katada T. Molecular cloning of a novel member of the Eukaryotic Polypeptide chain-releasing factors (eRF): its identification as eRF3 interacting with eRF1. J Biol Chem 1998, 273:22254-22259.
42. Malta-Vacas J, Aires C, Costa P, Conde AR, Ramos S, Martins AP, Monteiro C, Brito M. Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types. J Clin Pathol 2005, 58:621-625.
43. Tallheden T, Karlsson C, Brunner A, van der Lee J, Hagg R, Tommasini R, Lindahl A. Gene expression during redifferentiation of human articular chondrocytes. Osteoarthr Cartil 2004, 12:525-535.
44. Wu Y, Zhang X, Salmon M, Zehner ZE. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells 2007, 12:905-918.
45. Zhang CZY, Chen GG, Lai PBS. Transcription factor ZBP-89 in cancer growth and apoptosis. Biochim Biophys Acta 2010, 1806:36-41.
46. Lee KT, Lee YW, Lee JK, Choi SH, Rhee JC, Paik SS, Kong G. Overexpression of Id-1 is significantly associated with tumour angiogenesis in human pancreas cancers. Br J Cancer 2004, 90:1198-1203.
47. Lee TK, Man K, Ling MT, Wang XH, Wong YC, Lo CM, Poon RT, Ng IO, Fan ST. Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. Carcinogenesis 2003, 24:1729-1736.
48. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene 2001, 20:8334-8341.